SillaJen collaborates with MD Anderson and Yale Cancer Center in the U.S. for 바카라 토토 사이트 trials of anticancer drug candidate ‘BAL0891’”

[by Kang, In Hyo] SillaJen announced on April 3 that five prominent cancer research institutions in the U.S., including MD Anderson Cancer Center, Yale Cancer Center, and Montefiore Einstein Comprehensive Cancer Center, along with one institution in Korea, will participate in the 바카라 토토 사이트 trial of ‘BAL0891,’ an anticancer drug candidate for the treatment of acute myeloid leukemia (AML).

The company stated that these institutions were recently registered as participants on 바카라 토토 사이트Trials, a global 바카라 토토 사이트 trial registry. BAL0891 is a first-in-class dual inhibitor anticancer drug candidate designed to simultaneously inhibit ‘TTK (Threonine Tyrosine Kinase)’ and ‘PLK1 (Polo-Like Kinase 1)’. In addition, studies targeting various solid tumors are currently being conducted in both Korea and the United States.

SillaJen recently submitted an Investigational New Drug (IND) amendment application to the U.S. Food and Drug Administration (FDA) to expand the indication of BAL0891 to include acute myeloid leukemia. BAL0891 exerts a potent anticancer effect by simultaneously inhibiting two kinases, TTK and PLK1, which are essential for the cell division process in cancer cells, disrupting cancer cell division and inducing apoptosis.

Notably, in a pre바카라 토토 사이트 study using the MOLM-14 acute myeloid leukemia transplant model, BAL0891 demonstrated significant tumor growth inhibition and an improved survival rate, exhibiting anticancer efficacy even at low doses. Furthermore, when administered in combination with a ‘BCL-2 inhibitor,’ a widely used therapeutic agent for acute myeloid leukemia, a synergistic effect was observed.

Building on these promising pre바카라 토토 사이트 findings, SillaJen stated that globally recognized 바카라 토토 사이트 research institutes, including MD Anderson Cancer Center and Yale Cancer Center, have chosen to actively participate in the trial. The company further emphasized that the participation of these institutions is expected to enhance the 바카라 토토 사이트 credibility and global competitiveness of BAL0891.

This phase 1 바카라 토토 사이트 trial aims to assess the safety of BAL0891 as a monotherapy in patients with relapsed or refractory acute myeloid leukemia. Additionally, the study will establish the maximum tolerated dose (MTD) and determine the recommended 바카라 토토 사이트 dose (RP2D).

“Acute myeloid leukemia is a representative form of blood cancer characterized by a high relapse rate and poor prognosis. However, we anticipate that BAL0891’s dual inhibition mechanism will help overcome the limitations of existing treatments,” a SillaJen official expressed. “We are committed to continuous research and development (R&D) efforts to establish BAL0891 as a leading innovative novel drug in the treatment of solid tumors and blood cancers.”

Conversely, SillaJen plans to initiate 바카라 토토 사이트 trials for acute myeloid leukemia within the year. A portion of the pre바카라 토토 사이트 study findings will be presented at an international academic conference in the first half of the year.